NCT07917923
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Adverse Events (AEs) occurring after infusion and their proportions
Timeframe: From infusion to at least 1 year
Secondary (8)
Quantitative Myasthenia Gravis (QMG) score
Myasthenia Gravis Activities of Daily Living (MG-ADL) score
Time to maximum amplification (Tmax)
Maximum amplification (Cmax)
Area under the curve (AUC)
Show 3 moreShow less
Duration of Detectable Concentration (Tlast)
Chimeric Antigen Receptor T cell (CAR-T)-associated serum cytokines
Anti-drug antibodies (ADA) Response to GT802 Measured by Immunoassay.
Arms and interventions
GT802 Injection treatment groupExperimental
Participants with MG administered GT802 Injection
Biologicals: GT802 Injection
Sites
1 site in 1 country
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China